APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Research Report 2026

2 January 2026120 pages

Choose your research edition.

Industry ResearchHuman Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) include Weiguang Biological, CTBB, Shanghai RAAS, Nanyue Biopharming, Hualan Bio, Sinopharm, Guangdong Shuagnlin Bio-pharmacy, Boya-Bio and Beijing Tiantan Biological Products, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Company

Weiguang Biological

CTBB

Shanghai RAAS

Nanyue Biopharming

Hualan Bio

Sinopharm

Guangdong Shuagnlin Bio-pharmacy

Boya-Bio

Beijing Tiantan Biological Products

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Type

1.25g/25ml

10g/200ml

1g/20ml

2.5g/50ml

5g/100ml

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Application

Hospital

Clinic

Others

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue of Manufacturers (2021-2026) Table 9. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Product Type & Application Table 14. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Weiguang Biological Company Information Table 19. Weiguang Biological Business Overview Table 20. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 22. Weiguang Biological Recent Developments Table 23. CTBB Company Information Table 24. CTBB Business Overview Table 25. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 27. CTBB Recent Developments Table 28. Shanghai RAAS Company Information Table 29. Shanghai RAAS Business Overview Table 30. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 32. Shanghai RAAS Recent Developments Table 33. Nanyue Biopharming Company Information Table 34. Nanyue Biopharming Business Overview Table 35. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 37. Nanyue Biopharming Recent Developments Table 38. Hualan Bio Company Information Table 39. Hualan Bio Business Overview Table 40. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 42. Hualan Bio Recent Developments Table 43. Sinopharm Company Information Table 44. Sinopharm Business Overview Table 45. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 47. Sinopharm Recent Developments Table 48. Guangdong Shuagnlin Bio-pharmacy Company Information Table 49. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 50. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 52. Guangdong Shuagnlin Bio-pharmacy Recent Developments Table 53. Boya-Bio Company Information Table 54. Boya-Bio Business Overview Table 55. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 57. Boya-Bio Recent Developments Table 58. Beijing Tiantan Biological Products Company Information Table 59. Beijing Tiantan Biological Products Business Overview Table 60. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 62. Beijing Tiantan Biological Products Recent Developments Table 63. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 64. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026) & (K Units) Table 65. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2021-2026) Table 66. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2027-2032) & (K Units) Table 67. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2027-2032) Table 68. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2021-2026) & (US$ Million) Table 69. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2021-2026) Table 70. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2027-2032) & (US$ Million) Table 71. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2027-2032) Table 72. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 74. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 75. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 76. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2027-2032) & (US$ Million) Table 77. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 79. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 80. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2027-2032) & (US$ Million) Table 82. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 84. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 85. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 86. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2027-2032) & (US$ Million) Table 87. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 89. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 90. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 91. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2027-2032) & (US$ Million) Table 92. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 94. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 95. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2026) & (US$ Million) Table 96. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2027-2032) & (US$ Million) Table 97. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 98. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 99. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2026) Table 100. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2027-2032) Table 101. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 102. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 103. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2026) Table 104. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2027-2032) Table 105. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2026) & (US$/Unit) Table 106. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2027-2032) & (US$/Unit) Table 107. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 108. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 109. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2026) Table 110. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2027-2032) Table 111. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 112. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 113. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2026) Table 114. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2027-2032) Table 115. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2026) & (US$/Unit) Table 116. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2027-2032) & (US$/Unit) Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors List Table 120. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers List Table 121. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends Table 122. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers Table 123. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints Table 124. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Image Figure 5. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size (2021-2032) & (US$ Million) Figure 7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (2021-2032) & (K Units) Figure 8. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Price (US$/Unit) & (2021-2032) Figure 9. 1.25g/25ml Product Image Figure 10. 10g/200ml Product Image Figure 11. 1g/20ml Product Image Figure 12. 2.5g/50ml Product Image Figure 13. 5g/100ml Product Image Figure 14. Hospital Product Image Figure 15. Clinic Product Image Figure 16. Others Product Image Figure 17. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region in 2025 Figure 23. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region in 2025 Figure 24. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country in 2025 Figure 25. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 26. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country (2021-2032) Figure 27. United States Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country in 2025 Figure 30. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 31. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country (2021-2032) Figure 32. Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country in 2025 Figure 39. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country (2021-2032) Figure 41. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country in 2025 Figure 50. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 51. South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country (2021-2032) Figure 52. Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country in 2025 Figure 57. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country (2021-2032) Figure 59. Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2032) Figure 63. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2032) Figure 64. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price (US$/Unit) by Type (2021-2032) Figure 65. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2032) Figure 66. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2032) Figure 67. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price (US$/Unit) by Application (2021-2032) Figure 68. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Figure 69. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges

Scope & coverage.

Types
  • 1.25g/25ml
  • 10g/200ml
  • 1g/20ml
  • 2.5g/50ml
  • 5g/100ml
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Weiguang Biological
  • CTBB
  • Shanghai RAAS
  • Nanyue Biopharming
  • Hualan Bio
  • Sinopharm
  • Guangdong Shuagnlin Bio-pharmacy
  • Boya-Bio
  • Beijing Tiantan Biological Products

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size (2021-2032)
  4. 2.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (2021-2032)
  5. 2.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Average Price (2021-2032)
  6. 2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 1.25g/25ml
  9. 2.3.3 10g/200ml
  10. 2.3.4 1g/20ml
  11. 2.3.5 2.5g/50ml
  12. 2.3.6 5g/100ml
  13. 2.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital
  16. 2.4.3 Clinic
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Product Type & Application
  8. 3.8 Global Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Established Date
  9. 3.9 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Weiguang Biological
  2. 4.1.1 Weiguang Biological Company Information
  3. 4.1.2 Weiguang Biological Business Overview
  4. 4.1.3 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  6. 4.1.5 Weiguang Biological Recent Developments
  7. 4.2 CTBB
  8. 4.2.1 CTBB Company Information
  9. 4.2.2 CTBB Business Overview
  10. 4.2.3 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  12. 4.2.5 CTBB Recent Developments
  13. 4.3 Shanghai RAAS
  14. 4.3.1 Shanghai RAAS Company Information
  15. 4.3.2 Shanghai RAAS Business Overview
  16. 4.3.3 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  18. 4.3.5 Shanghai RAAS Recent Developments
  19. 4.4 Nanyue Biopharming
  20. 4.4.1 Nanyue Biopharming Company Information
  21. 4.4.2 Nanyue Biopharming Business Overview
  22. 4.4.3 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  24. 4.4.5 Nanyue Biopharming Recent Developments
  25. 4.5 Hualan Bio
  26. 4.5.1 Hualan Bio Company Information
  27. 4.5.2 Hualan Bio Business Overview
  28. 4.5.3 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  30. 4.5.5 Hualan Bio Recent Developments
  31. 4.6 Sinopharm
  32. 4.6.1 Sinopharm Company Information
  33. 4.6.2 Sinopharm Business Overview
  34. 4.6.3 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  36. 4.6.5 Sinopharm Recent Developments
  37. 4.7 Guangdong Shuagnlin Bio-pharmacy
  38. 4.7.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  39. 4.7.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  40. 4.7.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  42. 4.7.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  43. 4.8 Boya-Bio
  44. 4.8.1 Boya-Bio Company Information
  45. 4.8.2 Boya-Bio Business Overview
  46. 4.8.3 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  48. 4.8.5 Boya-Bio Recent Developments
  49. 4.9 Beijing Tiantan Biological Products
  50. 4.9.1 Beijing Tiantan Biological Products Company Information
  51. 4.9.2 Beijing Tiantan Biological Products Business Overview
  52. 4.9.3 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  54. 4.9.5 Beijing Tiantan Biological Products Recent Developments
5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Scenario by Region
  1. 5.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021-2032
  3. 5.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021-2026
  4. 5.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2027-2032
  5. 5.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2021-2032
  6. 5.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2021-2026
  7. 5.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2027-2032
  8. 5.4 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Facts & Figures by Country
  9. 5.4.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  11. 5.4.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Facts & Figures by Country
  15. 5.5.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  17. 5.5.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Facts & Figures by Country
  36. 5.7.1 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  38. 5.7.3 South America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.7.7 Colombia
  43. 5.8 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Facts & Figures by Country
  44. 5.8.1 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country: 2021 VS 2025 VS 2032
  45. 5.8.2 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2032)
  46. 5.8.3 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2021-2032)
  47. 5.8.4 Turkey
  48. 5.8.5 Saudi Arabia
  49. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032)
  2. 6.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032)
  5. 6.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032)
  2. 7.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032)
  5. 7.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Analysis
  2. 8.1.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process
  5. 8.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors
  8. 8.2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers
9 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Analyzing Market Dynamics
  1. 9.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends
  2. 9.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers
  3. 9.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges
  4. 9.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst